<?xml version='1.0' encoding='utf-8'?>
<document id="20007294"><sentence text="Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs." /><sentence text="Recombinant cytochrome P450 (P450) phenotyping, different approaches for estimating fraction metabolized (f(m)), and multiple measures of in vivo inhibitor exposure were tested for their ability to predict drug interaction magnitude in dogs" /><sentence text=" In previous reports, midazolam-ketoconazole interaction studies in dogs have been attributed to inhibition of CYP3A pathways" /><sentence text=" However, in vitro phenotyping studies demonstrated higher apparent intrinsic clearances (CL(int,app)) of midazolam with canine CYP2B11 and CYP2C21" /><sentence text=" Application of activity correction factors and isoform hepatic abundance to liver microsome CL(int,app) values further implicated CYP2B11 (f(m) &gt;or= 0" /><sentence text="89) as the dog enzyme responsible for midazolam- and temazepam-ketoconazole interactions in vivo" /><sentence text=" Mean area under the curve (AUC) in the presence of the inhibitor/AUC ratios from intravenous and oral midazolam interaction studies were predicted well with unbound K(i) and estimates of unbound hepatic inlet inhibitor concentrations and intestinal metabolism using the AUC-competitive inhibitor relationship"><entity charOffset="103-112" id="DDI-PubMed.20007294.s7.e0" text="midazolam" /></sentence><sentence text=" No interactions were observed in vivo with bufuralol, although significant interactions with bufuralol were predicted with fluoxetine via CYP2D and CYP2C pathways (&gt;2"><entity charOffset="44-53" id="DDI-PubMed.20007294.s8.e0" text="bufuralol" /><entity charOffset="94-103" id="DDI-PubMed.20007294.s8.e1" text="bufuralol" /><entity charOffset="124-134" id="DDI-PubMed.20007294.s8.e2" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.20007294.s8.e0" e2="DDI-PubMed.20007294.s8.e0" /><pair ddi="false" e1="DDI-PubMed.20007294.s8.e0" e2="DDI-PubMed.20007294.s8.e1" /><pair ddi="false" e1="DDI-PubMed.20007294.s8.e0" e2="DDI-PubMed.20007294.s8.e2" /><pair ddi="false" e1="DDI-PubMed.20007294.s8.e1" e2="DDI-PubMed.20007294.s8.e1" /><pair ddi="false" e1="DDI-PubMed.20007294.s8.e1" e2="DDI-PubMed.20007294.s8.e2" /></sentence><sentence text="45-fold) but not with clomipramine (&lt;2-fold)"><entity charOffset="22-34" id="DDI-PubMed.20007294.s9.e0" text="clomipramine" /></sentence><sentence text=" The minor caffeine-fluvoxamine interaction (1"><entity charOffset="11-19" id="DDI-PubMed.20007294.s10.e0" text="caffeine" /><entity charOffset="20-31" id="DDI-PubMed.20007294.s10.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.20007294.s10.e0" e2="DDI-PubMed.20007294.s10.e0" /><pair ddi="false" e1="DDI-PubMed.20007294.s10.e0" e2="DDI-PubMed.20007294.s10.e1" /></sentence><sentence text="78-fold) was slightly higher than predicted values based on determination of a moderate f(m) value for CYP1A1, although CYP1A2 may also be involved in caffeine metabolism" /><sentence text=" The findings suggest promise for in vitro approaches to drug interaction assessment in dogs, but they also highlight the need to identify improved substrate and inhibitor probes for canine P450s" /><sentence text="" /></document>